

Market Announcement

11 September 2023

Firebrick Pharma Limited (ASX: FRE) – Trading Halt

Description

The securities of Firebrick Pharma Limited ('FRE') will be placed in trading halt at the request of FRE, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 13 September 2023 or when the announcement is released to the market.

Issued by

Scarlette de Lavaine

Adviser, Listings Compliance

11 September 2023

Barbara Lim
Adviser, Listings Compliance
Level 40 Central Park
152-158 St George's Terrace
PERTH WA 6000

Via Email: tradinghaltsperth@asx.com.au

Dear Barbara

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, Firebrick Pharma Limited (ASX:FRE) (**Company**) hereby requests that its securities be placed into an immediate trading halt pending an announcement about the results of its Phase 3 Common Cold trial.

The Company requests that trading in its securities be halted until after the expected announcement is made regarding the above or until the market opens on Wednesday, 13 September 2023, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted.

Yours sincerely



Stephen Buckley
COMPANY SECRETARY